iPSC-ing into the future of cell therapy: expansion in a hollow-fiber bioreactor

Induced pluripotent stem cell (iPSC)-derived therapies offer unique opportunities in the pharmaceutical industry and clinical practice to shift cell therapy into an allogeneic paradigm. The development of these therapies requires high-quality iPSC banks generated via standardized workflows to minimize starting material bank-to-bank variability. In this article, two expert scientists share their experience working with iPSCs, the associated challenges, and the workflow and protocol optimizations needed to achieve doses relevant for clinical studies or further manufacturing. The transition from manual to automated iPSC expansion is described, followed by an exploration of how to effectively expand high-quality iPSCs in a functionally closed, automated, and scalable system using hollow-fiber perfusion technology.

Please enter your email to access content Read now